Oncology Knowledge into Practice Podcast

Immune checkpoint inhibitors are a relatively new treatment option for patients with metastatic, unresectable head and neck squamous cell carcinoma (HNSCC), and so they have not yet been incorporated into clinical practice guidelines. For this reason, we interview Professor Frederic Peyrade, Head of Clinical Research and Professor of Oncology, Antoine Lacassagne Cancer Centre, France, to get expert advice on incorporating immune checkpoint inhibitors into current treatment protocols.

References

- Grégoire V, et al. Ann Oncol. 2009; 20 Suppl 4: 121-2

- Dimitrios Colevas, et al. J Natl Compr Canc Netw. 2018 May; 16(5): 479-490

- Cohen, et al. J Immunother Cancer. 2019 Jul 15; 7(1): 184

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.

Several immune checkpoint inhibitors have indications in non small-cell lung cancer (NSCLC), but it is not always easy to decide which patients to treat when, and with which regimen. In today’s episode, we’ve invited Professor Martin Reck from the Lung Clinic Grosshansdorf in Germany to answer some of our questions about best practice when considering immune checkpoint inhibitors for patients with NSCLC.

References:

Postmus PE, et al. Annals of Oncology. 2017; 28: iv1-iv21

Socinski MA et al. JCO. 2019; 37(15_suppl): 9012-9012

Pacheco JM. Translational Lung Cancer Research. 2019; 8(5): 723-727

Funazo T et al. J Thorac Oncol. 2017; 12(9): e140-e141

Sridhar S et al. Clin Lung Cancer. 2019; 20(6): e601-e608

Chai Q-Q et al. Frontiers in Pharmacology. 2019; 10:1260

Peng M et al. OncoTargets and Therapy. 2018; 11: 7369-7383

Gadgeel S et al. JCO. 2020; 38(14): 1505-1517

Ettinger DS et al. J Natl Compr Canc Netw. 2017; 15(4): 504-535

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.

Several immune checkpoint inhibitors have indications in non small-cell lung cancer (NSCLC), but it is not always easy to decide which patients to treat when, and with which regimen. In today’s episode, we’ve invited Professor Martin Reck from the Lung Clinic Grosshansdorf in Germany to answer some of our questions about best practice when considering immune checkpoint inhibitors for patients with NSCLC.

References:

Postmus PE, et al. Annals of Oncology. 2017; 28: iv1-iv21

Socinski MA et al. JCO. 2019; 37(15_suppl): 9012-9012

Pacheco JM. Translational Lung Cancer Research. 2019; 8(5): 723-727

Funazo T et al. J Thorac Oncol. 2017; 12(9): e140-e141

Sridhar S et al. Clin Lung Cancer. 2019; 20(6): e601-e608

Chai Q-Q et al. Frontiers in Pharmacology. 2019; 10:1260

Peng M et al. OncoTargets and Therapy. 2018; 11: 7369-7383

Gadgeel S et al. JCO. 2020; 38(14): 1505-1517

Ettinger DS et al. J Natl Compr Canc Netw. 2017; 15(4): 504-535

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.

Histological specimens are recommended to assess a patient’s PD-L1 status; however, it is not always easy or even feasible to secure a histological specimen in advanced cancers such as stage IV NSCLC. Cytological specimens are typically used in this setting to assess other molecular markers such as ALK or ROS1 – should they also be used to assess PD-L1 status?
This episode summarises the evidence for and against a cytological approach, before joining Professor Frederique Penault-Llorca for her opinion on whether cytology should be used to assess PD-L1 status in real-world practice.

References:

Gosney J, et al. Lung Cancer. 2020; 141:101-106
Heymann J, et al. Cancer Cytopathology. 2017; 125(12): 896-907
Wagner C, et al. Eur Respir J. 2018; 52: Suppl. 62, PA2217.

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.

PD-L1 status has long been explored as a predictive biomarker for immune checkpoint inhibitors. However, the clinical evidence for its efficacy has been mixed, so how should PD-L1 status be used in clinical practice? 

In the first episode in this series on immuno-oncology, Dr Vaibhav Patel from the Icahn School of Medicine at Mount Sinai, New York, answers questions about how PD-L1 status can or cannot influence treatment decisions in oncology.

References:

Kulangara K, et al. Arch Pathol Lab Med. 2019; 143(3): 330-337

Mok S, et al. Lancet. 2019; 393(10183): 1819-1830

Pacheco J. Transl Lung Cancer Res. 2019; 8(5): 723-727

Xu Y, et al. Transl Lung Cancer Res. 2019; 8(4): 413-428

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.

In this bi-weekly podcast, cancer experts discuss game-changing topics in clinical oncology.

Produced by Oncology Knowledge into Practice (www.onckip.com), this podcast series will support and inform your practice in cancer management.

This podcast is intended for healthcare professionals only. Funding information is available in each episode's notes.

Access more free education today! Visit the website, follow us on Twitter (@onckip ) or connect on LinkedIn.

https://www.oncologyknowledgeintopractice.com/